Key points are not available for this paper at this time.
Older and high-risk adults frequently experience symptomatic RSV infection, with appreciable mortality; however, detailed data are lacking. Increased surveillance and research are needed to quantify population-based disease burden and facilitate RSV treatments and vaccine development.
Nguyen‐Van‐Tam et al. (Tue,) studied this question.